Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

Gemtuzumab Ozogamicin (GO) In Children With De Novo Acute Myeloid Leukemia (AML) Improves Event-Free Survival (EFS) By Reducing Relapse Risk – Results From The Randomized Phase III Children’s Oncology Group (COG) Trial, AAML0531

Alan S. Gamis, MD, MPH, Richard Aplenc, MD, PhD, Todd A. Alonzo, PhD, Lillian Sung, MD, PhD, Soheil Meshinchi, MD, PhD, Robert B. Gerbing, MA, Susana C. Raimondi, PhD, Betsy Hirsch, PhD, Samir Kahwash, MD, Amy Heerema-McKenney, MD, Laura Winter, PharmD, Kathleen Glick, CCRP, Stella M. Davies, MBBS, PhD, Patti Byron, MSN, RN, Franklin O. Smith, MD

Blood (2013) 122 (21): 355.

https://doi.org/10.1182/blood.V122.21.355.355

Published: 2013

Journal Articles

Abnormalities Of 12p Are Associated With High-Risk Acute Myeloid Leukemia: A Children’s Oncology Group Report

Betsy Hirsch, PhD, Todd A. Alonzo, PhD, Robert B. Gerbing, MA, Samir Kahwash, MD, Amy Heerema-McKenney, Richard Aplenc, MD, PhD, Lillian Sung, MD, PhD, Laura Winter, PharmD, Kathleen Glick, CCRP, Stella M. Davies, MBBS, PhD, Patti Byron, MSN, RN, Robert S. Lavey, MD, Franklin O. Smith, MD, Phoenix A. Ho, MD, Alan S. Gamis, MD, MPH, Soheil Meshinchi, MD, PhD, Susana C. Raimondi, PhD

Blood (2013) 122 (21): 612.

https://doi.org/10.1182/blood.V122.21.612.612

Published: 2013

Journal Articles

Elevated Expression of miR-181a and miR-155 Identify Pediatric AML Patients at High Risk of Induction Failure, A Report from Children's Oncology Group.

Blood (2012) 120 (21): 2388.

https://doi.org/10.1182/blood.V120.21.2388.2388

Published: 2012

Journal Articles

Outcome of Transplantation for Acute Leukemia in Down Syndrome

Blood (2012) 120 (21): 1991.

https://doi.org/10.1182/blood.V120.21.1991.1991

Published: 2012

Journal Articles

A Phase 2 Study of Bortezomib Combined with Reinduction Chemotherapy in Children and Young Adults with Recurrent, Refractory or Secondary Acute Myeloid Leukemia: A Children's Oncology Group (COG) Study

Terzah M. Horton, MD, PhD, John Perentesis, MD, Alan S. Gamis, MD, Todd A. Alonzo, PhD, Robert B. Gerbing, M.A., Jennifer Ballard, CRA, Kathleen Adlard, RN, Dianna Howard, MD, Franklin O. Smith, MD, Jeffrey A. Moscow, MD

Blood (2012) 120 (21): 3580.

https://doi.org/10.1182/blood.V120.21.3580.3580

Published: 2012

Journal Articles

Cryptic NUP98/NSD1 Translocations Are Highly Prevalent in FLT3/ITD-Positive Acute Myeloid Leukemia and Lead to High Rate of Induction Failure. Report From Children's Oncology Group

Fabiana Ostronoff, MD, Todd A. Alonzo, PhD, Robert B. Gerbing, M.A., Michael R. Loken, PhD, Laura Pardo, Richard Aplenc, MD, PhD, Lillian Sung, MD, PhD, Susana C. Raimondi, Betsy A. Hirsch, PhD, Samir Kahwash, MD, Amy Heerema-McKenney, MD, Laura Winter, PharmD, Kathleen Glick, CCRP, Patti Byron, MSN, RN, Robert S. Lavey, MD, Stella M. Davies, MBBS, PhD, Franklin O. Smith, MD, Alan S. Gamis, MD, MPH, Soheil Meshinchi, MD, PhD

Blood (2012) 120 (21): 529.

https://doi.org/10.1182/blood.V120.21.529.529

Published: 2012

Journal Articles

Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971

Alan S. Gamis, Todd A. Alonzo, Robert B. Gerbing, Joanne M. Hilden, April D. Sorrell, Mukta Sharma, Thomas W. Loew, Robert J. Arceci, Dorothy Barnard, John Doyle, Gita Massey, John Perentesis, Yaddanapudi Ravindranath, Jeffrey Taub, Franklin O. Smith

Blood (2011) 118 (26): 6752–6759.

https://doi.org/10.1182/blood-2011-04-350017

Published: 2011

Includes: Supplemental data

Journal Articles

Multidimensional Flow Cytometry Significantly Improves Upon the Morphologic Assessment of Post-Induction Marrow Remission Status – Comparison of Morphology and Multidimensional Flow Cytometry; A Report From the Children's Oncology Group AML Protocol AAML0531

Michael R. Loken, PhD, Todd A. Alonzo, PhD, Laura Pardo, Robert B. Gerbing, M.A., Richard Aplenc, MD, MSCE, Lillian Sung, MD, PhD, Susana C. Raimondi, PhD, Betsy A. Hirsch, PhD, Samir Kahwash, MD, Amy Heerema-McKenney, MD, Laura Winter, PharmD, Kathleen Glick, CCRP, Patti Byron, MSN, RN, Laura Fransisco, Tanya Wallas, MS, Stella M. Davies, MBBS, PhD, Franklin O. Smith, MD, Alan S. Gamis, MD, MPH, Soheil Meshinchi, MD, PhD

Blood (2011) 118 (21): 939.

https://doi.org/10.1182/blood.V118.21.939.939

Published: 2011

Journal Articles

Presence of Residual Disease Detected by Multidimensional Flow Cytometry Identifies Patients with AML At High Risk of Relapse – a Report From the Children's Oncology Group,

Blood (2011) 118 (21): 3545.

https://doi.org/10.1182/blood.V118.21.3545.3545

Published: 2011

Journal Articles

Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/ MLL -rearranged AML patients: results of an international study

Blood (2011) 117 (26): 7102–7111.

https://doi.org/10.1182/blood-2010-12-328302

Published: 2011

Includes: Supplemental data

Journal Articles

Remission Rates In Childhood Acute Myeloid Leukemia (AML) Utilizing a Dose-Intensive Induction Regimen with or without Gemtuzumab Ozogamicin (GO): Initial Results From the Children's Oncology Group Phase III Trial, AAML0531

Alan S Gamis, MD, MPH, Todd A Alonzo, PhD, Robert B Gerbing, MS, Richard Aplenc, MD, Lillian Sung, MD, PhD, Soheil Meshinchi, MD, PhD, Susana C. Raimondi, PhD, Betsy A. Hirsch, PhD, Samir Kahwash, MD, Amy Heerema-McKenney, MD, Laura Winter, PharmD, Kathleen Glick, CCRP, Patti Byron, RN, Laura Burden, Tanya Wallas, Stella M. Davies, MBBS, PhD, Franklin O. Smith, MD

Blood (2010) 116 (21): 182.

https://doi.org/10.1182/blood.V116.21.182.182

Published: 2010

Journal Articles

Clinical Impact of Additional Cytogenetic Aberrations and Complex Karyotype In Pediatric 11q23/ MLL -Rearranged AML: Results from an International Retrospective Study

Blood (2010) 116 (21): 762.

https://doi.org/10.1182/blood.V116.21.762.762

Published: 2010

Journal Articles

Severe Toxicities During Pediatric Acute Myeloid Leukemia Chemotherapy: A Report From the Children's Oncology Group.

Lillian Sung, MD, PhD, Richard Aplenc, MD, MSCE, Todd A. Alonzo, PhD, Robert B. Gerbing, MS, Soheil Meshinchi, MD, PhD, Laura Burden, CCRP, Susana C. Raimondi, PhD, Betsy A. Hirsch, PhD, Samir Kahwash, MD, Amy Heerema-McKenney, MD, Laura Winter, PharmD, Kathleen Glick, BA, CCRP, Patti Byron, MSN, RN, Tanya Wallas, MS, Franklin O. Smith, MD, Alan S. Gamis, MD, MPH

Blood (2010) 116 (21): 1071.

https://doi.org/10.1182/blood.V116.21.1071.1071

Published: 2010

Journal Articles

High Mortality In Extreme Hyperleukocytosis In Pediatric Acute Myeloid Leukemia: A Report From the Children's Oncology Group.

Lillian Sung, MD, PhD, Todd A. Alonzo, PhD, Robert B. Gerbing, MS, Richard Aplenc, MD, MSCE, Soheil Meshinchi, MD, PhD, Laura Burden, CCRP, Susana C. Raimondi, PhD, Betsy A. Hirsch, PhD, Samir Kahwash, MD, Amy Heerema-McKenney, MD, Laura Winter, PharmD, Kathleen Glick, BA, CCRP, Patti Byron, MSN, RN, Tanya Wallas, MS, Franklin O. Smith, MD, Alan S. Gamis, MD, MPH

Blood (2010) 116 (21): 1072.

https://doi.org/10.1182/blood.V116.21.1072.1072

Published: 2010

Journal Articles

Flow Cytometric Assessment of Post Induction Response In Patients with Sub-Optimal Morphologic Response to Induction Chemotherapy- A Report From the Children's Oncology Group AML Protocol AAML0531

Michael R. Loken, PhD, Todd A. Alonzo, PhD, Laura Pardo, Robert B. Gerbing, MA, Richard Aplenc, MD, Lillian Sung, MD, PhD, Susana C. Raimondi, PhD, Betsy A. Hirsch, PhD, Samir Kahwash, MD, Amy Heerema-McKenney, MD, Laura Winter, PharmD, Kathleen Glick, CCRP, Patti Byron, MSN, RN, Laura Burden, CCRP, Tanya Wallas, Stella M. Davies, MBBS, PhD, Franklin O. Smith, MD, Soheil Meshinchi, MD, PhD, Alan S. Gamis, MD, MPH

Blood (2010) 116 (21): 2740.

https://doi.org/10.1182/blood.V116.21.2740.2740

Published: 2010

Journal Articles

Personalized medicine for AML?

Franklin O. Smith

Blood (2010) 116 (15): 2622–2623.

https://doi.org/10.1182/blood-2010-07-296418

Published: 2010

Journal Articles

High Expression of the Very Late Antigen (VLA)-4 (CD49d) Integrin Predicts for Reduced Risk of Relapse and Better Outcome in Pediatric Acute Myeloid Leukemia (AML): A Report From the Children's Oncology Group.

Walter B. Walter, MD, PhD, Todd A. Alonzo, PhD, Robert B. Gerbing, MS, Franklin O. Smith, MD, Susana C. Raimondi, PhD, Betsy A. Hirsch, PhD, Alan S. Gamis, MD, Janet L. Franklin, MD, MPH, Craig A. Hurwitz, MD, Michael R. Loken, PhD, Soheil Meshinchi, MD, PhD

Blood (2009) 114 (22): 1592.

https://doi.org/10.1182/blood.V114.22.1592.1592

Published: 2009

Journal Articles

Reducing the Risk for Transplant Related Mortality After Allogeneic Hematopoietic Cell Transplantation: How Much Progress Has Been Made?.

John Horan, MD, MPH, Brent R. Logan, PhD, Manza-A. Agovi, MPH, Hillard M Lazarus, MD, Andrea Bacigalupo, MD, Karen Ballen, Rodrigo Martino, Mark B. Juckett, MD, Hanna J. Khoury, MD, Christopher Bredeson, MD, Vikas Gupta, Franklin O. Smith, MD, Gregory Hale, Matthew Carabasi, MD, Philip L. McCarthy, MD, J. Douglas Rizzo, MD, MS, Marcelo C. Pasquini, MD

Blood (2009) 114 (22): 649.

https://doi.org/10.1182/blood.V114.22.649.649

Published: 2009

Journal Articles

Novel prognostic subgroups in childhood 11q23/ MLL -rearranged acute myeloid leukemia: results of an international retrospective study

Blood (2009) 114 (12): 2489–2496.

https://doi.org/10.1182/blood-2009-04-215152

Published: 2009

Includes: Supplemental data

Journal Articles

Donor-Recipient Matching at the HLA-C Locus and Early Outcomes after Unrelated Umbilical Cord Blood Transplant (UCBT)

Mary Eapen, MBBS, John Klein, PhD, Guillermo Sanz, MD, PhD, Claudio Anasetti, MD, Joan Garcia, MD, Eliane Gluckman, MD, Mary M. Horowitz, MD, MS, Gesine Koegler, MD, Mary Laughlin, MD, Gerard Michel, MD, Stephen R Spellman, MS, Franklin O. Smith, MD, Vanderson Rocha, MD, PhD

Blood (2008) 112 (11): 153.

https://doi.org/10.1182/blood.V112.11.153.153

Published: 2008

NARROW

Gemtuzumab Ozogamicin (GO) In Children With De Novo Acute Myeloid Leukemia (AML) Improves Event-Free Survival (EFS) By Reducing Relapse Risk – Results From The Randomized Phase III Children’s Oncology Group (COG) Trial, AAML0531

Abnormalities Of 12p Are Associated With High-Risk Acute Myeloid Leukemia: A Children’s Oncology Group Report

Elevated Expression of miR-181a and miR-155 Identify Pediatric AML Patients at High Risk of Induction Failure, A Report from Children's Oncology Group.

Outcome of Transplantation for Acute Leukemia in Down Syndrome

A Phase 2 Study of Bortezomib Combined with Reinduction Chemotherapy in Children and Young Adults with Recurrent, Refractory or Secondary Acute Myeloid Leukemia: A Children's Oncology Group (COG) Study

Cryptic NUP98/NSD1 Translocations Are Highly Prevalent in FLT3/ITD-Positive Acute Myeloid Leukemia and Lead to High Rate of Induction Failure. Report From Children's Oncology Group

Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971

Multidimensional Flow Cytometry Significantly Improves Upon the Morphologic Assessment of Post-Induction Marrow Remission Status – Comparison of Morphology and Multidimensional Flow Cytometry; A Report From the Children's Oncology Group AML Protocol AAML0531

Presence of Residual Disease Detected by Multidimensional Flow Cytometry Identifies Patients with AML At High Risk of Relapse – a Report From the Children's Oncology Group,

Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/ MLL -rearranged AML patients: results of an international study

Remission Rates In Childhood Acute Myeloid Leukemia (AML) Utilizing a Dose-Intensive Induction Regimen with or without Gemtuzumab Ozogamicin (GO): Initial Results From the Children's Oncology Group Phase III Trial, AAML0531

Clinical Impact of Additional Cytogenetic Aberrations and Complex Karyotype In Pediatric 11q23/ MLL -Rearranged AML: Results from an International Retrospective Study

Severe Toxicities During Pediatric Acute Myeloid Leukemia Chemotherapy: A Report From the Children's Oncology Group.

High Mortality In Extreme Hyperleukocytosis In Pediatric Acute Myeloid Leukemia: A Report From the Children's Oncology Group.

Flow Cytometric Assessment of Post Induction Response In Patients with Sub-Optimal Morphologic Response to Induction Chemotherapy- A Report From the Children's Oncology Group AML Protocol AAML0531

Personalized medicine for AML?

High Expression of the Very Late Antigen (VLA)-4 (CD49d) Integrin Predicts for Reduced Risk of Relapse and Better Outcome in Pediatric Acute Myeloid Leukemia (AML): A Report From the Children's Oncology Group.

Reducing the Risk for Transplant Related Mortality After Allogeneic Hematopoietic Cell Transplantation: How Much Progress Has Been Made?.

Novel prognostic subgroups in childhood 11q23/ MLL -rearranged acute myeloid leukemia: results of an international retrospective study

Donor-Recipient Matching at the HLA-C Locus and Early Outcomes after Unrelated Umbilical Cord Blood Transplant (UCBT)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only